Abbott Seeks Expanded Labeling For CardioMEMS HF Monitor Based On GUIDE HF Results

The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.

• Source: Abbott

The GUIDE HF trial missed its primary endpoint, but the trial's investigators contend the trial still showed that Abbott ’s CardioMEMS HF pulmonary artery pressure monitoring system can help reduce heart failure hospitalizations in patients with moderate heart failure.

JoAnn Lindenfeld of Vanderbilt University in Nashville presented the full one-year results from the 1,000-patient randomized arm of GUIDE HF...

More from Clinical Trials

More from R&D